A fortnightly call where Amati Managers aim to share opinions on key events over the previous weeks and highlight areas of investment interest. 10 – 15 minutes of concise comment at 8:45am every second Tuesday. If you haven’t already registered to watch “Amati Insights”, please click here to subscribe to the mailing list.

Amati insights
24 February 2026 – Do androids dream of electric sheep?…
Humanoid robots and physical AI have become some of the most talked-about themes in technology investing. In this Amati Insights discussion, Amati fund managers Mikhail Zverev and Graeme Bencke explore the rise of physical AI and the technologies enabling the…
View >
Amati insights
10 February 2026 – Great software sell-off of 2026 –…
The rapid advancement of artificial intelligence has sparked concerns that many software businesses could face disruption as AI becomes increasingly capable of writing code, analysing data and automating knowledge-based tasks. In this edition of Amati Insights, Amati fund managers Mikhail…
View >
Amati insights
27 January 2026 – Memory super-cycle: from demand boom to…
Is AI creating a new memory supercycle? In this Amati Insights discussion, Amati fund managers Mikhail Zverev and Graeme Bencke examine the growing importance of memory semiconductors as AI workloads place increasing demands on data centres, networks and connected devices.…
View >
Amati insights
13 January 2026 – Greenlandia: Part Two
Greenland is attracting growing international attention due to its significant natural resource potential and strategic importance in the Arctic. In this edition of Amati Insights, Amati CEO Paul Jourdan speaks with Eldur Olafsson, founder and CEO of Amaroq Minerals, about…
View >
Amati insights
13 January 2026 – Greenlandia: Part One
Why has Greenland become the focus of increasing international attention? In this edition of Amati Insights, Amati fund managers Paul Jourdan and Mark Smith explore Greenland's growing strategic importance as a source of critical minerals and rare earth elements. The…
View >
Amati insights
2 December 2025 – Post Budget Review
In our latest Amati Insights discussion, Dr Paul Jourdan and Gregor Paterson from the WS Amati UK Listed Smaller Companies Fund share their thoughts on the recent UK budget — from its drawn-out lead-up and unexpected spending increases to its…
View >
Amati insights
18 November 2025 – RFID 2.0: accelerating adoption
 Recent conversations with the industry suggest that RFID and other wireless IoT technologies continue to unlock new transformative applications – from retail to healthcare to everyday consumer life. Join Amati Global Innovation fund managers Mikhail Zverev and Graeme Bencke…
View >
Amati insights
4 November 2025 – Alzheimer’s Disease: diagnostics revolution
 Alzheimer's Disease is one of the most pressing unmet clinical needs and is a huge cost to healthcare systems and societies. Recent developments in Alzheimer's diagnostics are nothing short of revolutionary and promise to unlock improved patient outcomes and…
View >
Amati insights
21 October 2025 – Photonics and optical communications in the…
Photonics and optical communications have been key enablers of the digital revolution. With AI, the industry is entering a hyper-growth stage. Join Amati managers Mikhail Zverev and Graeme Bencke to hear why the transition to optical data communication is inevitable…
View >
Amati insights
7 October 2025 – Defence Update
 The nature of warfare is changing and innovations in electronic warfare, advanced communications and drone and missile defence are developing at pace. Join Gregor Paterson from the Amati UK Small Cap Fund and Graeme Bencke from the Amati Global…
View >
Amati insights
23 September 2025 – Back to school: Innovation beyond AI
Amati Insights restarts after the break with a look back at Innovation progress and breakthroughs during the summer, which was anything but quiet. The market is singularly focused on generative AI and the data centre boom, but there is a…
View >
Amati insights
24 June 2025 – Medical Diagnostics
Medical diagnostics is an exciting growth area. Demand for diagnostics from patients and health professionals is combined with and amplified by the innovation and biological discovery in biomarkers and testing techniques. Join Dr Gareth Blades and Mikhail Zverev from Amati…
View >

Important Information

This recording is provided for informational purposes only and does not represent an offer or solicitation to buy or sell any securities; nor does it provide all the facts needed to make an informed decision about investing in any of Amati’s funds, services or portfolio companies. Prospective investors should always read the relevant product documentation, which contains full details of the costs and charges as well as specific risk warnings. These documents are available at http://amatiglobal.com .

Past performance is not a reliable guide to future performance. The value of investments and the income from them may go down as well as up and investors may not get back the amount they originally invested. Smaller companies, and in particular those companies quoted on the Alternative Investment Market (AIM), typically carry much more risk than investment in companies listed on the Main Market of the London Stock Exchange. Further, the tax treatment of such investments is not guaranteed and is subject to change. In respect of global markets, the return on investment may increase or decrease as a result of exchange rate movements, while certain products may be invested across a limited range of industries and sectors and be subject to higher risk and volatility.

Please note that this presentation is intended primarily for authorised financial advisers. Any non-professional investors joining the presentation today, or viewing it at a later date, should take careful note of the information above and seek professional advice before  considering any investment.

Amati Global Investors Limited, 8 Coates Crescent, Edinburgh, EH3 7AL (Registered No. SC199908) Tel: 0131 503 9100. Email: info@amatiglobal.com. Website: http://amatiglobal.com Issued by Amati Global Investors Limited, which is authorised and regulated by the Financial Conduct Authority.